Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with ref…
SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus Nephritis+4 more
Estimated
~$10 – $8,750
CRISPR TherapeuticsNCT06925542
Phase 2
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic scler…
Diffuse Cutaneous Systemic Sclerosis
Estimated
~$10 – $8,750
Novartis PharmaceuticalsNCT06470048
Phase 2
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (d…
Diffuse Cutaneous Systemic Sclerosis
Estimated
~$10 – $8,750
Mediar TherapeuticsNCT07287670
Phase 1
A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects With Severe Refractory Autoimmune Diseases
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune disea…
Lupus NephritisSystemic Lupus ErythematosusSystemic Sclerosis (SSc)+1 more
Estimated
~$10 – $8,750
Miltenyi Biomedicine GmbHNCT06708845